ENHANCE: Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

Nubeqa (darolutamide) - Bayer, Orion Corp

enzalutamide - Generic mfg.

Firmagon (degarelix) - Astellas, Ferring

triptorelin - Generic mfg.

goserelin acetate - Generic mfg.

Orgovyx (relugolix) - Takeda, Sumitomo Pharma, Pfizer

Erleada (apalutamide) - J&J

leuprolide acetate for depot suspension - Generic mfg.

abiraterone acetate - Generic mfg.

ENHANCE: Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer (clinicaltrials.gov) - Sep 5, 2026 - P3 | N=1500 | Recruiting | Sponsor: University College, London | Not yet recruiting ➔ Recruiting
Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

http://clinicaltrials.gov/ct2/show/NCT07751133

Sep 5, 2026